glp 1 agonists tirzepatide gip/glp 1-agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes comparing cardiovascular and kidney outcomes

Similarly, in a pooled analysis of results with semaglutide, a significant improvement was found in the annual impairment of eGFR, which was particularly pronounced in those with a baseline eGFR between 30 and 60 ml/min., but which remained significant in those with a higher baseline eGFR [30]

Your physician will design an integrated treatment plan that maximizes synergistic effects while ensuring safety and efficacy across all modalities

Evidence-based IV therapy protocols, patient education, and revenue strategies to grow your practice

Resistance training can help, but this requires active attention

GLP-1s mimic a hormone important to regulating hunger and metabolism

Addressing these directly helps with informed decision-making